Brandon Peters, MD
Family Medicine · Elizabeth City, NCNPI 1487757035
Payments from drug & device makers
Across 546 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- Amgen$970
- Boehringer Ingelheim$934
- Johnson & Johnson$889
- Lilly USA, LLC$741
- plus $5K from 32 others
What the payments were for
- Speaking & faculty fees$200%
- Food & beverage$11,725100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 73 | $1,814 |
| AstraZeneca | 67 | $1,781 |
| Amgen | 33 | $970 |
| Boehringer Ingelheim | 57 | $934 |
| Johnson & Johnson | 70 | $889 |
| Lilly USA, LLC | 35 | $741 |
| AbbVie(2 entities) | 19 | $507 |
| GSK | 11 | $487 |
| Astellas Pharma US Inc | 11 | $452 |
| Novartis | 19 | $416 |
| Sanofi-aventis U.S. LLC | 25 | $389 |
| Pfizer | 23 | $350 |
| Merck | 22 | $313 |
| Phathom Pharmaceuticals, Inc. | 4 | $232 |
| Idorsia Pharmaceuticals US Inc | 9 | $201 |
| Bayer | 13 | $197 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $196 |
| Corcept Therapeutics | 4 | $169 |
| Mylan Specialty L.p. | 4 | $88 |
| Kowa Pharmaceuticals America, Inc. | 4 | $59 |
| Endo USA, Inc. | 2 | $56 |
| Exact Sciences | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Corium, LLC | 2 | $45 |
| Amarin Pharma, Inc. | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Gilead | 2 | $38 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| Eisai Inc. | 2 | $32 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Sonex Health, Inc. | 1 | $28 |
| Dexcom, Inc. | 2 | $26 |
| Abbott | 1 | $23 |
| Dermira, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,753 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 192 | $155,769 |
| OzempicSemaglutide | 112 | $126,533 |
| EliquisApixaban | 170 | $126,400 |
| XareltoRivaroxaban | 78 | $73,127 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $68,553 |
| FarxigaDapagliflozin Propanediol | 67 | $58,083 |
| MounjaroTirzepatide | 44 | $57,290 |
| JanuviaSitagliptin Phosphate | 41 | $34,626 |
| RybelsusSemaglutide | 23 | $34,592 |
| TrulicityDulaglutide | 29 | $34,167 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 35 | $30,188 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $19,411 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $15,618 |
| MyrbetriqMirabegron | 24 | $13,348 |
| LinzessLinaclotide | 11 | $11,940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $934 | $175,180213 claims |
| Novo NordiskOzempic, Rybelsus | $1,814 | $161,125135 claims |
| PfizerEliquis, Premarin | $350 | $133,456190 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25 | $741 | $96,22894 claims |
| Johnson & JohnsonXarelto, Invokana | $889 | $79,88290 claims |
| GSKTrelegy Ellipta | $487 | $68,55381 claims |
| AstraZenecaFarxiga, Symbicort | $1,781 | $63,57485 claims |
| MerckJanuvia, Janumet | $313 | $50,24467 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $389 | $30,18835 claims |
| Astellas Pharma US IncMyrbetriq | $452 | $13,34824 claims |
| AbbVieLinzess | $507 | $11,94011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Elizabeth City
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.